img

Global Blood Plasma Derivatives Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Blood Plasma Derivatives Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Blood plasma is the liquid component of blood constituting of water along with plasma components such as immunoglobulin, electrolytes, glucose, clotting factors, electrolytes, and hormones. It plays a crucial role in maintaining the electrolyte and osmotic balance while preventing infection and blood disorders in the body. Plasma derivatives are the concentrates of specific proteins, which require pooling of plasma from large number of donors. For instance, they require more than hundred plasma donations to produce sufficient immunoglobulin to treat an immune-deficient patient for one year. They are obtained by the process of fractionation where protein concentrates are separated and then clinically used.
Due to the COVID-19 pandemic, the global Blood Plasma Derivatives market size was US$ 30890 million in 2022 and is forecast to a readjusted size of US$ 47030 million by 2034 with a CAGR of 5.7% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Albumin accounting for % of the Blood Plasma Derivatives global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The growth of the global blood plasma derivatives market is majorly driven by increase in prevalence of life-threatening disorders, especially hemophilia. Other factors boosting the market growth include rise in adoption of blood plasma derivatives products, upsurge in geriatric population across the world, and increase in awareness about blood & plasma donation. However, factors such as high cost of plasma derivative-based therapy and post-operative risks associated with plasma replacement therapy hamper the market growth. Conversely, the development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high potential in untapped markets in the emerging economies are expected to provide lucrative growth opportunities for the market.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Blood Plasma Derivatives market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Blood Plasma Derivatives market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Blood Plasma Derivatives market. Readers of the report can become informed about current and future trends of the global Blood Plasma Derivatives market and how they will impact market growth during the forecast period.



By Company


Grifols
SK Plasma
Fusion Health Care
Biotest AG
Green Cross Corporation
Baxter International
LFB
Octapharma AG
CSL Limited
Takeda
China Biologic Products
Kedrion Biopharma
BDI Pharma
Bayer AG
Hualan Biological Engineering
Segment by Type
Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others

Segment by Application


Hospitals
Clinics
Other End Users
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Blood Plasma Derivatives in global and regional level.
Chapter 3Detailed analysis of Blood Plasma Derivatives companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Blood Plasma Derivatives revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Plasma Derivatives Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Albumin
1.2.3 Factor VIII
1.2.4 Factor IX
1.2.5 Immunoglobulin
1.2.6 Hyperimmune Globulin
1.2.7 Others
1.3 Market by Application
1.3.1 Global Blood Plasma Derivatives Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other End Users
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Blood Plasma Derivatives Market Size (2018-2034)
2.2 Blood Plasma Derivatives Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Blood Plasma Derivatives Market Size by Region (2018-2024)
2.4 Global Blood Plasma Derivatives Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Blood Plasma Derivatives Countries Ranking by Market Size
3 Blood Plasma Derivatives Competitive by Company
3.1 Global Blood Plasma Derivatives Revenue by Players
3.1.1 Global Blood Plasma Derivatives Revenue by Players (2018-2024)
3.1.2 Global Blood Plasma Derivatives Market Share by Players (2018-2024)
3.2 Global Blood Plasma Derivatives Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Blood Plasma Derivatives Revenue
3.4 Global Blood Plasma Derivatives Market Concentration Ratio
3.4.1 Global Blood Plasma Derivatives Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Plasma Derivatives Revenue in 2022
3.5 Global Key Players of Blood Plasma Derivatives Head office and Area Served
3.6 Global Key Players of Blood Plasma Derivatives, Product and Application
3.7 Global Key Players of Blood Plasma Derivatives, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Blood Plasma Derivatives Breakdown Data by Type
4.1 Global Blood Plasma Derivatives Historic Revenue by Type (2018-2024)
4.2 Global Blood Plasma Derivatives Forecasted Revenue by Type (2024-2034)
5 Global Blood Plasma Derivatives Breakdown Data by Application
5.1 Global Blood Plasma Derivatives Historic Market Size by Application (2018-2024)
5.2 Global Blood Plasma Derivatives Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Blood Plasma Derivatives Revenue by Company (2021-2024)
6.2 North America Blood Plasma Derivatives Revenue by Type (2018-2034)
6.3 North America Blood Plasma Derivatives Revenue by Application (2018-2034)
6.4 North America Blood Plasma Derivatives Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Blood Plasma Derivatives Revenue by Company (2021-2024)
7.2 Europe Blood Plasma Derivatives Revenue by Type (2018-2034)
7.3 Europe Blood Plasma Derivatives Revenue by Application (2018-2034)
7.4 Europe Blood Plasma Derivatives Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Blood Plasma Derivatives Revenue by Company (2021-2024)
8.2 Asia Pacific Blood Plasma Derivatives Revenue by Type (2018-2034)
8.3 Asia Pacific Blood Plasma Derivatives Revenue by Application (2018-2034)
8.4 Asia Pacific Blood Plasma Derivatives Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Blood Plasma Derivatives Revenue by Company (2021-2024)
9.2 Latin America Blood Plasma Derivatives Revenue by Type (2018-2034)
9.3 Latin America Blood Plasma Derivatives Revenue by Application (2018-2034)
9.4 Latin America Blood Plasma Derivatives Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Blood Plasma Derivatives Revenue by Company (2021-2024)
10.2 Middle East and Africa Blood Plasma Derivatives Revenue by Type (2018-2034)
10.3 Middle East and Africa Blood Plasma Derivatives Revenue by Application (2018-2034)
10.4 Middle East and Africa Blood Plasma Derivatives Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Grifols
11.1.1 Grifols Company Details
11.1.2 Grifols Business Overview
11.1.3 Grifols Blood Plasma Derivatives Products and Services
11.1.4 Grifols Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.1.5 Grifols Blood Plasma Derivatives SWOT Analysis
11.1.6 Grifols Recent Development
11.2 SK Plasma
11.2.1 SK Plasma Company Details
11.2.2 SK Plasma Business Overview
11.2.3 SK Plasma Blood Plasma Derivatives Products and Services
11.2.4 SK Plasma Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.2.5 SK Plasma Blood Plasma Derivatives SWOT Analysis
11.2.6 SK Plasma Recent Development
11.3 Fusion Health Care
11.3.1 Fusion Health Care Company Details
11.3.2 Fusion Health Care Business Overview
11.3.3 Fusion Health Care Blood Plasma Derivatives Products and Services
11.3.4 Fusion Health Care Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.3.5 Fusion Health Care Blood Plasma Derivatives SWOT Analysis
11.3.6 Fusion Health Care Recent Development
11.4 Biotest AG
11.4.1 Biotest AG Company Details
11.4.2 Biotest AG Business Overview
11.4.3 Biotest AG Blood Plasma Derivatives Products and Services
11.4.4 Biotest AG Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.4.5 Biotest AG Blood Plasma Derivatives SWOT Analysis
11.4.6 Biotest AG Recent Development
11.5 Green Cross Corporation
11.5.1 Green Cross Corporation Company Details
11.5.2 Green Cross Corporation Business Overview
11.5.3 Green Cross Corporation Blood Plasma Derivatives Products and Services
11.5.4 Green Cross Corporation Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.5.5 Green Cross Corporation Blood Plasma Derivatives SWOT Analysis
11.5.6 Green Cross Corporation Recent Development
11.6 Baxter International
11.6.1 Baxter International Company Details
11.6.2 Baxter International Business Overview
11.6.3 Baxter International Blood Plasma Derivatives Products and Services
11.6.4 Baxter International Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.6.5 Baxter International Blood Plasma Derivatives SWOT Analysis
11.6.6 Baxter International Recent Development
11.7 LFB
11.7.1 LFB Company Details
11.7.2 LFB Business Overview
11.7.3 LFB Blood Plasma Derivatives Products and Services
11.7.4 LFB Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.7.5 LFB Blood Plasma Derivatives SWOT Analysis
11.7.6 LFB Recent Development
11.8 Octapharma AG
11.8.1 Octapharma AG Company Details
11.8.2 Octapharma AG Business Overview
11.8.3 Octapharma AG Blood Plasma Derivatives Products and Services
11.8.4 Octapharma AG Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.8.5 Octapharma AG Blood Plasma Derivatives SWOT Analysis
11.8.6 Octapharma AG Recent Development
11.9 CSL Limited
11.9.1 CSL Limited Company Details
11.9.2 CSL Limited Business Overview
11.9.3 CSL Limited Blood Plasma Derivatives Products and Services
11.9.4 CSL Limited Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.9.5 CSL Limited Blood Plasma Derivatives SWOT Analysis
11.9.6 CSL Limited Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Blood Plasma Derivatives Products and Services
11.10.4 Takeda Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.10.5 Takeda Blood Plasma Derivatives SWOT Analysis
11.10.6 Takeda Recent Development
11.11 China Biologic Products
11.11.1 China Biologic Products Company Details
11.11.2 China Biologic Products Business Overview
11.11.3 China Biologic Products Blood Plasma Derivatives Products and Services
11.11.4 China Biologic Products Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.11.5 China Biologic Products Recent Development
11.12 Kedrion Biopharma
11.12.1 Kedrion Biopharma Company Details
11.12.2 Kedrion Biopharma Business Overview
11.12.3 Kedrion Biopharma Blood Plasma Derivatives Products and Services
11.12.4 Kedrion Biopharma Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.12.5 Kedrion Biopharma Recent Development
11.13 BDI Pharma
11.13.1 BDI Pharma Company Details
11.13.2 BDI Pharma Business Overview
11.13.3 BDI Pharma Blood Plasma Derivatives Products and Services
11.13.4 BDI Pharma Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.13.5 BDI Pharma Recent Development
11.14 Bayer AG
11.14.1 Bayer AG Company Details
11.14.2 Bayer AG Business Overview
11.14.3 Bayer AG Blood Plasma Derivatives Products and Services
11.14.4 Bayer AG Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.14.5 Bayer AG Recent Development
11.15 Hualan Biological Engineering
11.15.1 Hualan Biological Engineering Company Details
11.15.2 Hualan Biological Engineering Business Overview
11.15.3 Hualan Biological Engineering Blood Plasma Derivatives Products and Services
11.15.4 Hualan Biological Engineering Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024)
11.15.5 Hualan Biological Engineering Recent Development
12 Blood Plasma Derivatives Market Dynamics
12.1 Blood Plasma Derivatives Industry Trends
12.2 Blood Plasma Derivatives Market Drivers
12.3 Blood Plasma Derivatives Market Challenges
12.4 Blood Plasma Derivatives Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Blood Plasma Derivatives Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Albumin
Table 3. Key Players of Factor VIII
Table 4. Key Players of Factor IX
Table 5. Key Players of Immunoglobulin
Table 6. Key Players of Hyperimmune Globulin
Table 7. Key Players of Others
Table 8. Global Blood Plasma Derivatives Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 9. Global Blood Plasma Derivatives Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 10. Global Blood Plasma Derivatives Revenue by Region (2018-2024) & (US$ Million)
Table 11. Global Blood Plasma Derivatives Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 12. Global Blood Plasma Derivatives Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 13. Global Blood Plasma Derivatives Revenue by Players (2018-2024) & (US$ Million)
Table 14. Global Blood Plasma Derivatives Market Share by Players (2018-2024)
Table 15. Global Top Blood Plasma Derivatives Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Plasma Derivatives as of 2022)
Table 16. Ranking of Global Top Blood Plasma Derivatives Companies by Revenue (US$ Million) in 2022
Table 17. Global 5 Largest Players Market Share by Blood Plasma Derivatives Revenue (CR5 and HHI) & (2018-2024)
Table 18. Global Key Players of Blood Plasma Derivatives, Headquarters and Area Served
Table 19. Global Key Players of Blood Plasma Derivatives, Product and Application
Table 20. Global Key Players of Blood Plasma Derivatives, Date of Enter into This Industry
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Blood Plasma Derivatives Market Size by Type (2018-2024) & (US$ Million)
Table 23. Global Blood Plasma Derivatives Revenue Market Share by Type (2018-2024)
Table 24. Global Blood Plasma Derivatives Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 25. Global Blood Plasma Derivatives Revenue Market Share by Type (2024-2034)
Table 26. Global Blood Plasma Derivatives Market Size by Application (2018-2024) & (US$ Million)
Table 27. Global Blood Plasma Derivatives Revenue Market Share by Application (2018-2024)
Table 28. Global Blood Plasma Derivatives Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 29. Global Blood Plasma Derivatives Revenue Market Share by Application (2024-2034)
Table 30. North America Blood Plasma Derivatives Revenue by Company (2021-2024) & (US$ Million)
Table 31. North America Blood Plasma Derivatives Revenue by Type (2018-2024) & (US$ Million)
Table 32. North America Blood Plasma Derivatives Revenue by Type (2024-2034) & (US$ Million)
Table 33. North America Blood Plasma Derivatives Revenue by Application (2018-2024) & (US$ Million)
Table 34. North America Blood Plasma Derivatives Revenue by Application (2024-2034) & (US$ Million)
Table 35. North America Blood Plasma Derivatives Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 36. North America Blood Plasma Derivatives Revenue by Country (2018-2024) & (US$ Million)
Table 37. North America Blood Plasma Derivatives Revenue by Country (2024-2034) & (US$ Million)
Table 38. Europe Blood Plasma Derivatives Revenue by Company (2021-2024) & (US$ Million)
Table 39. Europe Blood Plasma Derivatives Revenue by Type (2018-2024) & (US$ Million)
Table 40. Europe Blood Plasma Derivatives Revenue by Type (2024-2034) & (US$ Million)
Table 41. Europe Blood Plasma Derivatives Revenue by Application (2018-2024) & (US$ Million)
Table 42. Europe Blood Plasma Derivatives Revenue by Application (2024-2034) & (US$ Million)
Table 43. Europe Blood Plasma Derivatives Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 44. Europe Blood Plasma Derivatives Revenue by Country (2018-2024) & (US$ Million)
Table 45. Europe Blood Plasma Derivatives Revenue by Country (2024-2034) & (US$ Million)
Table 46. Asia Pacific Blood Plasma Derivatives Revenue by Company (2021-2024) & (US$ Million)
Table 47. Asia Pacific Blood Plasma Derivatives Revenue by Type (2018-2024) & (US$ Million)
Table 48. Asia Pacific Blood Plasma Derivatives Revenue by Type (2024-2034) & (US$ Million)
Table 49. Asia Pacific Blood Plasma Derivatives Revenue by Application (2018-2024) & (US$ Million)
Table 50. Asia Pacific Blood Plasma Derivatives Revenue by Application (2024-2034) & (US$ Million)
Table 51. Asia-Pacific Blood Plasma Derivatives Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 52. Asia Pacific Blood Plasma Derivatives Revenue by Region (2018-2024) & (US$ Million)
Table 53. Asia Pacific Blood Plasma Derivatives Revenue by Region (2024-2034) & (US$ Million)
Table 54. Latin America Blood Plasma Derivatives Revenue by Company (2021-2024) & (US$ Million)
Table 55. Latin America Blood Plasma Derivatives Revenue by Type (2018-2024) & (US$ Million)
Table 56. Latin America Blood Plasma Derivatives Revenue by Type (2024-2034) & (US$ Million)
Table 57. Latin America Blood Plasma Derivatives Revenue by Application (2018-2024) & (US$ Million)
Table 58. Latin America Blood Plasma Derivatives Revenue by Application (2024-2034) & (US$ Million)
Table 59. Latin America Blood Plasma Derivatives Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 60. Latin America Blood Plasma Derivatives Revenue by Country (2018-2024) & (US$ Million)
Table 61. Latin America Blood Plasma Derivatives Revenue by Country (2024-2034) & (US$ Million)
Table 62. Middle East and Africa Blood Plasma Derivatives Revenue by Company (2021-2024) & (US$ Million)
Table 63. Middle East and Africa Blood Plasma Derivatives Revenue by Type (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Blood Plasma Derivatives Revenue by Type (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Blood Plasma Derivatives Revenue by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Blood Plasma Derivatives Revenue by Application (2024-2034) & (US$ Million)
Table 67. Middle East and Africa Blood Plasma Derivatives Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 68. Middle East and Africa Blood Plasma Derivatives Revenue by Country (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Blood Plasma Derivatives Revenue by Country (2024-2034) & (US$ Million)
Table 70. Grifols Company Details
Table 71. Grifols Business Overview
Table 72. Grifols Blood Plasma Derivatives Product and Services
Table 73. Grifols Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 74. Grifols Blood Plasma Derivatives SWOT Analysis
Table 75. Grifols Recent Development
Table 76. SK Plasma Company Details
Table 77. SK Plasma Business Overview
Table 78. SK Plasma Blood Plasma Derivatives Product and Services
Table 79. SK Plasma Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 80. SK Plasma Blood Plasma Derivatives SWOT Analysis
Table 81. SK Plasma Recent Development
Table 82. Fusion Health Care Company Details
Table 83. Fusion Health Care Business Overview
Table 84. Fusion Health Care Blood Plasma Derivatives Product and Services
Table 85. Fusion Health Care Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 86. Fusion Health Care Blood Plasma Derivatives SWOT Analysis
Table 87. Fusion Health Care Recent Development
Table 88. Biotest AG Company Details
Table 89. Biotest AG Business Overview
Table 90. Biotest AG Blood Plasma Derivatives Product and Services
Table 91. Biotest AG Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 92. Biotest AG Blood Plasma Derivatives SWOT Analysis
Table 93. Biotest AG Recent Development
Table 94. Green Cross Corporation Company Details
Table 95. Green Cross Corporation Business Overview
Table 96. Green Cross Corporation Blood Plasma Derivatives Product and Services
Table 97. Green Cross Corporation Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 98. Green Cross Corporation Blood Plasma Derivatives SWOT Analysis
Table 99. Green Cross Corporation Recent Development
Table 100. Baxter International Company Details
Table 101. Baxter International Business Overview
Table 102. Baxter International Blood Plasma Derivatives Product and Services
Table 103. Baxter International Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 104. Baxter International Blood Plasma Derivatives SWOT Analysis
Table 105. Baxter International Recent Development
Table 106. LFB Company Details
Table 107. LFB Business Overview
Table 108. LFB Blood Plasma Derivatives Product and Services
Table 109. LFB Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 110. LFB Blood Plasma Derivatives SWOT Analysis
Table 111. LFB Recent Development
Table 112. Octapharma AG Company Details
Table 113. Octapharma AG Business Overview
Table 114. Octapharma AG Blood Plasma Derivatives Product and Services
Table 115. Octapharma AG Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 116. Octapharma AG Blood Plasma Derivatives SWOT Analysis
Table 117. Octapharma AG Recent Development
Table 118. CSL Limited Company Details
Table 119. CSL Limited Business Overview
Table 120. CSL Limited Blood Plasma Derivatives Product and Services
Table 121. CSL Limited Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 122. CSL Limited Blood Plasma Derivatives SWOT Analysis
Table 123. CSL Limited Recent Development
Table 124. Takeda Company Details
Table 125. Takeda Business Overview
Table 126. Takeda Blood Plasma Derivatives Product and Services
Table 127. Takeda Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 128. Takeda Blood Plasma Derivatives SWOT Analysis
Table 129. Takeda Recent Development
Table 130. China Biologic Products Company Details
Table 131. China Biologic Products Business Overview
Table 132. China Biologic Products Blood Plasma Derivatives Product and Services
Table 133. China Biologic Products Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 134. China Biologic Products Recent Development
Table 135. Kedrion Biopharma Company Details
Table 136. Kedrion Biopharma Business Overview
Table 137. Kedrion Biopharma Blood Plasma Derivatives Product and Services
Table 138. Kedrion Biopharma Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 139. Kedrion Biopharma Recent Development
Table 140. BDI Pharma Company Details
Table 141. BDI Pharma Business Overview
Table 142. BDI Pharma Blood Plasma Derivatives Product and Services
Table 143. BDI Pharma Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 144. BDI Pharma Recent Development
Table 145. Bayer AG Company Details
Table 146. Bayer AG Business Overview
Table 147. Bayer AG Blood Plasma Derivatives Product and Services
Table 148. Bayer AG Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 149. Bayer AG Recent Development
Table 150. Hualan Biological Engineering Company Details
Table 151. Hualan Biological Engineering Business Overview
Table 152. Hualan Biological Engineering Blood Plasma Derivatives Product and Services
Table 153. Hualan Biological Engineering Blood Plasma Derivatives Revenue in Blood Plasma Derivatives Business (2018-2024) & (US$ Million)
Table 154. Hualan Biological Engineering Recent Development
Table 155. Blood Plasma Derivatives Market Trends
Table 156. Blood Plasma Derivatives Market Drivers
Table 157. Blood Plasma Derivatives Market Challenges
Table 158. Blood Plasma Derivatives Market Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Blood Plasma Derivatives Product Picture
Figure 2. Global Blood Plasma Derivatives Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Blood Plasma Derivatives Market Share by Type: 2022 VS 2034
Figure 4. Albumin Features
Figure 5. Factor VIII Features
Figure 6. Factor IX Features
Figure 7. Immunoglobulin Features
Figure 8. Hyperimmune Globulin Features
Figure 9. Others Features
Figure 10. Global Blood Plasma Derivatives Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 11. Global Blood Plasma Derivatives Market Share by Application: 2022 VS 2034
Figure 12. Hospitals
Figure 13. Clinics
Figure 14. Other End Users
Figure 15. Blood Plasma Derivatives Report Years Considered
Figure 16. Global Blood Plasma Derivatives Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 17. Global Blood Plasma Derivatives Market Size 2018-2034 (US$ Million)
Figure 18. Global Blood Plasma Derivatives Market Size Market Share by Region: 2022 VS 2034
Figure 19. Global Blood Plasma Derivatives Revenue Market Share by Region in 2018 VS 2022
Figure 20. Global Blood Plasma Derivatives Revenue Market Share Forecast by Region (2024-2034)
Figure 21. Global Top 10 Blood Plasma Derivatives Countries Ranking by Market Size (US$ Million) in 2022
Figure 22. Global Blood Plasma Derivatives Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 23. Global Blood Plasma Derivatives Market Share by Players in 2022
Figure 24. Global Top Blood Plasma Derivatives Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Plasma Derivatives as of 2022)
Figure 25. The Top 10 and 5 Players Market Share by Blood Plasma Derivatives Revenue in 2022
Figure 26. North America Blood Plasma Derivatives Revenue Market Share by Company in 2022
Figure 27. North America Blood Plasma Derivatives Revenue Market Share by Type (2018-2034)
Figure 28. North America Blood Plasma Derivatives Revenue Market Share by Application (2018-2034)
Figure 29. North America Blood Plasma Derivatives Revenue Share by Country (2018-2034)
Figure 30. U.S. Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 31. Canada Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 32. Europe Blood Plasma Derivatives Revenue Market Share by Company in 2022
Figure 33. Europe Blood Plasma Derivatives Revenue Market Share by Type (2018-2034)
Figure 34. Europe Blood Plasma Derivatives Revenue Market Share by Application (2018-2034)
Figure 35. Europe Blood Plasma Derivatives Revenue Share by Country (2018-2034)
Figure 36. Germany Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 37. France Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 38. U.K. Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 39. Italy Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 40. Russia Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 41. Asia Pacific Blood Plasma Derivatives Revenue Market Share by Company in 2022
Figure 42. Asia Pacific Blood Plasma Derivatives Revenue Market Share by Type (2018-2034)
Figure 43. Asia Pacific Blood Plasma Derivatives Revenue Market Share by Application (2018-2034)
Figure 44. Asia Pacific Blood Plasma Derivatives Revenue Share by Region (2018-2034)
Figure 45. China Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 46. Japan Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 47. South Korea Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 48. India Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 49. Australia Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 50. Taiwan Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 51. Indonesia Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 52. Thailand Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 53. Malaysia Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 54. Philippines Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 55. Vietnam Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 56. Latin America Blood Plasma Derivatives Revenue Market Share by Company in 2022
Figure 57. Latin America Blood Plasma Derivatives Revenue Market Share by Type (2018-2034)
Figure 58. Latin America Blood Plasma Derivatives Revenue Market Share by Application (2018-2034)
Figure 59. Latin America Blood Plasma Derivatives Revenue Share by Country (2018-2034)
Figure 60. Mexico Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 61. Brazil Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 62. Argentina Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 63. Middle East and Africa Blood Plasma Derivatives Revenue Market Share by Company in 2022
Figure 64. Middle East and Africa Blood Plasma Derivatives Revenue Market Share by Type (2018-2034)
Figure 65. Middle East and Africa Blood Plasma Derivatives Revenue Market Share by Application (2018-2034)
Figure 66. Middle East and Africa Blood Plasma Derivatives Revenue Share by Country (2018-2034)
Figure 67. Turkey Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 68. Saudi Arabia Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 69. U.A.E Blood Plasma Derivatives Revenue (2018-2034) & (US$ Million)
Figure 70. Grifols Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 71. SK Plasma Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 72. Fusion Health Care Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 73. Biotest AG Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 74. Green Cross Corporation Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 75. Baxter International Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 76. LFB Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 77. Octapharma AG Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 78. CSL Limited Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 79. Takeda Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 80. China Biologic Products Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 81. Kedrion Biopharma Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 82. BDI Pharma Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 83. Bayer AG Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 84. Hualan Biological Engineering Revenue Growth Rate in Blood Plasma Derivatives Business (2018-2024)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed